Repositioning Candidate Details
| Candidate ID: | R0661 |
| Source ID: | DB04956 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Afelimomab |
| Synonyms: | Afelimomab |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | Afelimomab (also known as Fab 2 or MAK 195F) is an anti-TNF-α monoclonal antibody. Administration of 195F reduces the concentration of interleukin-6 in patients with sepsis. |
| CAS Number: | 156227-98-4 |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in sepsis and septicemia. |
| DrugBank Pharmacology: | Afelimomab is the F(ab')2 fragment of a murine anti-TNF-alpha antibody, and has been evaluated in clinical trials in septic patients. The results suggest that the drug is well tolerated, and may be of benefit in certain groups of patients with sepsis. Afelimomab is safe, biologically active, and well tolerated in patients with severe sepsis, reduces 28-day all-cause mortality, and attenuates the severity of organ dysfunction in patients with elevated interleukin-6 levels. |
| DrugBank MoA: | -- |
| Targets: | Tumor necrosis factor |
| Inclusion Criteria: | Target associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|